AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Date, time and room of presentation of release dated September 5, 2019, should read: Monday, September 9, 2019, from 12:30-12:55 p.m. EDT in Adams (instead of Tuesday, September 10, 2019, from 3:00-3:25 p.m. EDT in Holmes I).
The corrected release reads:
GENPREX TO PRESENT AT THE H.C. WAINWRIGHT 21ST ANNUAL GLOBAL INVESTMENT CONFERENCE
(NASDAQ: ), a clinical-stage gene therapy company, today announced that it will present at the H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019 in New York City.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's presentation and will be available for one-on-one meetings.
Genprex will present at the H.C. Wainwright 21st Annual Global Investment Conference as follows:
Date: Monday, September 9, 2019
Time: 12:30-12:55 p.m. EDT
Venue: Lotte New York Palace Hotel, New York City
Room: Adams (4th Floor)
Several networking opportunities are still available to investors or delegates of other companies that may wish to meet the Genprex team one-on-one. Those interested in setting a meeting are asked to contact the company at .
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at or follow Genprex on , and .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex on cancer. Risks and uncertainties associated with Genprex and its lead product candidate Oncoprex are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View source version on businesswire.com:
